Uncategorized
Refocus completes patient enrollment for potential presbyopia treatment
Enrollment is complete for a phase 3 clinical trial of the VisAbility Micro-Insert System for treatment of presbyopia, according to press release from Refocus Group. Three-hundred and sixty subjects are enrolled at 13 clinical trial sites in the U.S.The company also announced it has secured $15 million in new financing from MedCare Investments Funds and WP Global Partners.